Evidence map›Paper›PMID 35470961›Full record

ArticleCNS neuroscience & therapeutics2022

Amyloid-β protein and MicroRNA-384 in NCAM-Labeled exosomes from peripheral blood are potential diagnostic markers for Alzheimer's disease.

Ying Li, Shuang Meng, Wu Di, Ming Xia, Lei Dong, Yue Zhao, Sihai Ling, Jing He, Xiaoxing Xue, Xiali Chen and 1 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS neuroscience & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Extracellular Vesicles in Tauopathies: Mechanisms and Applications.International journal of molecular sciences · 2026
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Ying LiClinical Laboratory of Beijing Anding Hospital, Capital Medical University, Beijing, China.
Shuang MengState Key Laboratory for Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Beijing, China.
Wu DiClinical Laboratory of Xuanwu Hospital, Capital Medical University, Beijing, China.
Ming XiaClinical Laboratory of Minhang Hospital, Fudan University, Shanghai, China.
Lei DongClinical Laboratory of Air Force General Hospital, Chinese People's Liberation Army, Beijing, China.
Yue ZhaoClinical Laboratory of Xuanwu Hospital, Capital Medical University, Beijing, China.
Sihai LingClinical Laboratory of Beijing Anding Hospital, Capital Medical University, Beijing, China.
Jing HeClinical Laboratory of Beijing Anding Hospital, Capital Medical University, Beijing, China.
Xiaoxing XueClinical Laboratory of Beijing Anding Hospital, Capital Medical University, Beijing, China.
Xiali ChenClinical Laboratory of Beijing Anding Hospital, Capital Medical University, Beijing, China.
Chengeng LiuClinical Laboratory of Beijing Anding Hospital, Capital Medical University, Beijing, China.ORCID 0000-0003-1455-8171
Capital Medical University · CNAir Force General Hospital PLA · CNFudan University · CNNational Institute for Communicable Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe aimed to establish a method to determine whether amyloid-β (Aβ) protein and miR-384 in peripheral blood neural cell adhesion molecule (NCAM)/ATP-binding cassette transporter A1 (ABCA1) dual-labeled exosomes may serve as diagnostic markers for the diagnosis of Alzheimer's disease (AD).

methodsThis was a multicenter study using a two-stage design. The subjects included 45 subjective cognitive decline (SCD) patients, 50 amnesic mild cognitive impairment (aMCI) patients, 40 AD patients, and 30 controls in the discovery stage. The results were validated in the verification stage in 47 SCD patients, 45 aMCI patients, 45 AD patients, and 30 controls. NCAM single-labeled and NCAM/ABCA1 double-labeled exosomes in the peripheral blood were captured and detected by immunoassay.

resultsThe Aβ42, Aβ

conclusionThis study, for the first time, established a method that sorts specific surface marker exosomes using a two-step immune capture technology. The plasma NCAM/ABCA1 dual-labeled exosomal Aβ

Indexed as

Alzheimer DiseaseCognitive DysfunctionExosomesMicroRNAsAmyloid beta-PeptidesBiomarkersHumansNeural Cell Adhesion MoleculesPeptide Fragmentstau ProteinsAmyloid beta-PeptidesBiomarkersMicroRNAsMIRN384 microRNA, humanNeural Cell Adhesion MoleculesPeptide Fragmentstau ProteinsAlzheimer's diseaseATP-binding cassette transporter A1biomarkerexosomeneural cell adhesion molecule

Identifiers

PMID35470961
PMCPMC9160455
OpenAlexW4224949050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.